Item 8.01. Other Events.

On July 6, 2021, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that it had entered into a clinical trial collaboration agreement with Vaccitech plc ("Vaccitech") to evaluate an innovative therapeutic combination of the Company's RNAi therapeutic, AB-729 and Vaccitech's immunotherapeutic, VTP-300, for the treatment of subjects with chronic hepatitis B virus infection who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor therapy. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit Number     Description

  99.1               Press release dated July 6, 2021
104                Cover page interactive data file (formatted as inline XBRL).

© Edgar Online, source Glimpses